PanGIA Pancreas

About PanGIA Biotech

PanGIA Biotech is pioneering an AI-driven, multi-fluid diagnostic platform centered on a non-invasive 'True Liquid Biopsy' using urine. The company's PanGIA Analysis System (PAS) applies machine learning to colorimetric biomolecular profiles to detect early-stage cancers with the goal of improving accuracy, accessibility, and patient comfort over traditional methods like blood tests or tissue biopsies. While its lead PanGIA Prostate assay is in use globally for diagnostic research, the company is navigating the path toward FDA approval and commercial scale-up to address the significant global need for better early cancer detection.

Therapeutic Areas

Other Pancreatic Cancer Drugs